Early tumour response assessment may avoid serious immune-related adverse events in nivolumab and ipilimumab combination therapy for stage IV melanoma

Br J Dermatol. 2022 Mar;186(3):587-588. doi: 10.1111/bjd.20879. Epub 2021 Dec 21.

Authors

T Maeda¹, A Hiura¹, J Uehara¹, R Toyoshima¹, T Nakagawa¹, K Yoshino¹

Affiliation

¹ Department of Dermatologic Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.

PMID: 34747503
DOI: 10.1111/bjd.20879

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Humans
Ipilimumab / adverse effects
Melanoma* / pathology
Nivolumab / adverse effects
Skin Neoplasms* / pathology

Substances

Ipilimumab
Nivolumab